NCT06328036 2024-12-30Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaNational Cancer Institute (NCI)Phase 2 Withdrawn